[Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer].
Radiation therapy is a treatment option for curative management of localized and locally advanced prostate cancer. Depending on tumor stage and constellation of risk factors (PSA level, findings on digital rectal examination, and Gleason score), various forms of radiotherapy are applied. In addition to the sole use of external beam radiotherapy, brachytherapy with radioactive seeds is also employed as stand-alone treatment in patients with low risk factors and in early clinical stages. Increasing risk of recurrence requires more intensive therapies which can be accomplished by adding hormone deprivation therapy and/or intensifying radiation therapy (dose escalation). Combined approaches using brachytherapy and percutaneous radiotherapy are also initiated in these cases. If hormone ablation therapy is administered, this should occur over a course of 3-36 months as neoadjuvant, concommitant and/or adjuvant treatment, depending on the risk of recurrence.
Böhmer
D
D
Klinik für Strahlentherapie, Charité-Universitätsmedizin Berlin, Campus-Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin. dirk.boehmer@charite.de
Wenz
F
F
Martin
T
T
Sedlmayr
F
F
Hinkelbein
W
W
Wiegel
T
T
D001859:Bone Neoplasms / Q000473:pathology / Q000556:secondary; D001918:Brachytherapy; D018450:Disease Progression; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage